Provided by Tiger Fintech (Singapore) Pte. Ltd.

Abbott Laboratories

129.08
-1.4200-1.09%
Volume:1.42M
Turnover:185.01M
Market Cap:223.87B
PE:16.76
High:131.27
Open:130.92
Low:128.91
Close:130.50
Loading ...

Abbott Agrees to Integrate Libre Data With Epic's Record System

MT Newswires Live
·
21 hours ago

Abbott Integrates Libre's Data with Epic's Electronic Health Record System, Providing Healthcare Professionals Seamless Glucose Monitoring Information

PR Newswire
·
Yesterday

Abbott Laboratories (NYSE:ABT) Unveils Breakthrough Leadless Pacemaker Advances In New Clinical Trials

Simply Wall St.
·
Yesterday

PBH or ABT: Which Is the Better Value Stock Right Now?

Zacks
·
28 Apr

3 Dividend Stocks to Buy and Hold for the Next Decade

Motley Fool
·
28 Apr

The Zacks Analyst Blog Highlights Abbott Laboratories, Boston Scientific and Medtronic

Zacks
·
28 Apr

Abbott Laboratories (NYSE:ABT) Is Doing The Right Things To Multiply Its Share Price

Simply Wall St.
·
28 Apr

Abbott Laboratories Says Investigational Pacemaker Shows Safety, Performance

MT Newswires Live
·
28 Apr

Abbott Laboratories: Strategic Advancements and Market Positioning with Volt PFA Platform Drive Buy Rating

TIPRANKS
·
28 Apr

Abbott announces new AVEIR data, initiates trial for pacing technology

TIPRANKS
·
28 Apr

Abbott announces new data from its Volt CE Mark Study

TIPRANKS
·
28 Apr

BRIEF-Abbott Laboratories Says New Clinical Study Data Showcase Long-Term, Sustained Benefits Of Abbott's Volt™ Pfa System For Patients With Afib

Reuters
·
27 Apr

Abbott Laboratories - Volt Pfa System Shows Strong 12-Month Results

THOMSON REUTERS
·
27 Apr

Abbott Laboratories - Only 2.7% Experienced Safety Endpoint Event After 12 Months

THOMSON REUTERS
·
27 Apr

Abbott Laboratories - 83.5% Paf and 58.1% Persaf Patients Arrhythmia-Free After 12 Months

THOMSON REUTERS
·
27 Apr

New Clinical Study Data Showcase Long-Term, Sustained Benefits of Abbott's Volt™ Pfa System for Patients With Afib

THOMSON REUTERS
·
27 Apr

New Clinical Study Data Showcase Long-Term, Sustained Benefits of Abbott's Volt™ PFA System for Patients with AFib

PR Newswire
·
27 Apr

Tariffs Cast a Shadow on Abbott's 2025 View: Time to Sell ABT Stock?

Zacks
·
26 Apr

EPD Growth in Emerging Market Supports Abbott Stock Amid Macro Woes

Zacks
·
24 Apr

Medtronic Seeks FDA Marketing Approval for Interoperable Pump, SmartGuard Algorithm

MT Newswires Live
·
24 Apr